EUnetHTA Joint Action 3 (2016-20)

EMA-EUnetHTA meeting Dec 2016 – Final minutes

EMA-EUnetHTA Joint Work Plan for 2017-2020

This is the EMA-EUnetHTA Joint Work Plan for 2017-2020 EMA-EUnetHTA work plan 2017 – 2020 – for publication

An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report

An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report WP7 Activity 1 Report Template for deliverable 7.1 Annex 1_agency data Annex 2_case studies

Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Project plan_PTJA03_Alectinib_final

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.